Skip to content
Reflections of yellow marbles on metal holders
Reflections of yellow marbles on metal holders

Life Sciences

Our global Life Sciences practice comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, veterinary, medtech, diagnostics and healthcare sectors.

The practice operates on a cross-border basis and covers the full spectrum of legal support. We advise on mergers and acquisitions, commercial transactions (including licensing and collaborations), IP (both contentious and non-contentious), capital markets and finance, regulatory and dispute resolution. Our international network ensures that we have a ready resource of expertise in a number of jurisdictions, including those in emerging markets, and that we are well positioned to advise on cross-border work.

We have won a reputation for providing far-sighted advice to some of the world’s leading life science companies – including GlaxoSmithKline, Pfizer, UCB, Merck, Bayer and Novartis.

News & insights

shipping container and crane

Publications: 16 NOVEMBER 2021

The UK’s trade remedies regime

The creation of an independent UK trade remedies regime is a critical and under-reported aspect of the UK’s new trade policy. Going forward, the UK’s newfound ability to shape its own trade remedies…

Read more
Windows on a modern glass and metal building

Publications: 07 OCTOBER 2021

Record-breaking M&A run continues at pace

Dealmaking across the globe continues to break records, as investors take advantage of benign market conditions to deploy capital at an accelerating pace.

Read more
Person wearing gloves experimenting using petri dish and red liquid

Blog Post: 15 SEPTEMBER 2021

Fibrogen v Akebia: Court of Appeal judgment on sufficiency of functional claims

The Court of Appeal (Birss LJ, Floyd LJ and Phillips LJ) handed down its judgment in Fibrogen v Akebia on 24 August 2021, overturning Arnold LJ (another Court of Appeal judge) on his judgment on…

Read more
Image of a skyscraper with blue tinted windows

Publications: 08 JULY 2021

Dramatic pause in global Special Purpose Acquisition Companies (SPACs) clouds the outlook

The extraordinary boom in U.S. SPAC formations continued in Q1 but declined steeply from April onwards. Few believe the trend is over, but a period of greater uncertainty seems likely. SPACs are now…

Read more

Recognition

Related links

Life Sciences Hub

We report on EU and national regulatory, compliance, intellectual property and transactional developments in the sector.

Read more

CRISPR microsite

The characterisation and optimisation of the CRISPR (also known as CRISPR-Cas) system for gene editing and other applications, is undoubtedly one of the most powerful and ground breaking advances in the history of biotechnology.

Go to microsite

Growth Capital microsite

Allen & Overy is an engaged and active player in the growth company ecosystem.

Go to microsite

Cannabis microsite

According to UN estimates, the global cannabis market is currently worth approximately USD150 billion annually. 

Go to microsite

Download our sector brochure

Life sciences A&O red molecules

An insight in to our Life Science and Healthcare sector 2021

Our global Life Sciences and Healthcare sector comprises a multi-disciplinary team. We act for companies and their investors across the industry, including in the pharmaceuticals, biotech, animal health, consumer health, med tech, and diagnostics sectors.

Related content

Global trends in merger control enforcement

Record levels in the first half of 2018 and considerable contraction in the second.